The Experts below are selected from a list of 288 Experts worldwide ranked by ideXlab platform
Deng Wan-jun - One of the best experts on this subject based on the ideXlab platform.
-
Drug Therapy of Chronic Heart Failure in the Elderly
Advances in Cardiovascular Diseases, 2008Co-Authors: Deng Wan-junAbstract:In elderly people,chronic heart failure is the leading cause of hospitalization in the Western Hemisphere.The prevalence of the disease increases with age,as do related healthcare costs.Moreover,changes of physiological function and other complications make Drug Therapy problematic in the elderly.This article reviews the recent progress in Drug Therapy of chronic heart failure in the elderly.
Thomas Müller - One of the best experts on this subject based on the ideXlab platform.
-
Drug Therapy in patients with Parkinson’s disease
Translational Neurodegeneration, 2012Co-Authors: Thomas MüllerAbstract:Parkinson`s disease (PD) is a progressive, disabling neurodegenerative disorder with onset of motor and non-motor features. Both reduce quality of life of PD patients and cause caregiver burden. This review aims to provide a survey of possible therapeutic options for treatment of motor and non motor symptoms of PD and to discuss their relation to each other. MAO-B-Inhibitors, NMDA antagonists, dopamine agonists and levodopa with its various application modes mainly improve the dopamine associated motor symptoms in PD. This armentarium of PD Drugs only partially influences the onset and occurrence of non motor symptoms. These PD features predominantly result from non dopaminergic neurodegeneration. Autonomic features, such as seborrhea, hyperhidrosis, orthostatic syndrome, salivation, bladder dysfunction, gastrointestinal disturbances, and neuropsychiatric symptoms, such as depression, sleep disorders, psychosis, cognitive dysfunction with impaired execution and impulse control may appear. Drug Therapy of these non motor symptoms complicates long-term PD Drug Therapy due to possible occurrence of Drug interactions, - side effects, and altered pharmacokinetic behaviour of applied compounds. Dopamine substituting compounds themselves may contribute to onset of these non motor symptoms. This complicates the differentiation from the disease process itself and influences therapeutic options, which are often limited because of additional morbidity with necessary concomitant Drug Therapy.
Robert M. Ward - One of the best experts on this subject based on the ideXlab platform.
-
Drug Therapy of the fetus.
Journal of clinical pharmacology, 1993Co-Authors: Robert M. WardAbstract:The fetus has become an intended object of Drug Therapy administered through the mother with the successful prevention of hyaline membrane disease with glucocorticoids. Maternal Drug treatment has now been undertaken for a variety of fetal problems, including arrhythmias, congestive heart failure, infections, and inborn errors of adrenal metabolism. Interestingly, this planned maternal Drug exposure during pregnancy coincided with increasing concerns during the last two decades about inadvertent transplacental exposure of the fetus to licit and illicit Drugs. Efforts to direct Drug Therapy to the fetus have pointed out important gaps in knowledge of the pharmacology of the maternal-placental-fetal-unit (MPFU), whereas other observations illustrated recognized principles of the pharmacology of the MPFU. Many of these principles fit the basic framework of pharmacokinetics: absorption, distribution, metabolism and excretion. Rapid changes in maternal-placental physiology and fetal development during gestation, however, lead to dramatic variations in these processes throughout pregnancy.
Edwin C Webb - One of the best experts on this subject based on the ideXlab platform.
-
collaborative Drug Therapy management by pharmacists 2003
Pharmacotherapy, 2003Co-Authors: Raymond W Hammond, Amy H Schwartz, Marla J Campbell, Tami L Remington, Susan K Chuck, Melissa M Blair, Ann M Vassey, Raylene M Rospond, Sheryl J Herner, Edwin C WebbAbstract:Since publication of the initial ACCP position statement on CDTM by pharmacists in 1997, the public, government, and much of the health care community at large have come to better appreciate the growing complexity of providing effective and safe Drug Therapy in today's health care environment. Increased interest in the issues of cost and quality of Drug use is evident in the increasing coverage of the issue in the lay press and professional literature. This represents real progress, as well as real opportunity, for pharmacists. It also heightens the potential for a better understanding of the vital role that pharmacists can play in addressing these concerns. The percentage of patients who take several Drugs for chronic diseases will continue to increase. Based on current trends, the number of patients who lack adequate access to care, or who receive either suboptimal, inappropriate, or unnecessarily expensive Drug Therapy for their acute and chronic diseases, will increase. Even as financial and human resources are increasingly strained within the current health care system, costs will continue to rise unless changes are made. Fortunately, qualified pharmacists are prepared, capable, and willing to help address a significant portion of these challenges. The public, many health care providers, some legislators, and a few insurers now recognize that pharmacists, because of their education and training in Drug Therapy, are well positioned both to accept additional responsibility for patient care and to provide services that make a real difference in health care quality and outcomes. The health care programs administered by the U.S. Public Health Service, the armed forces, and the Veterans Health Administration, as well as 38 states, now support pharmacist participation in CDTM. Pharmacists, working in an interdisciplinary structure with physicians and other health care providers, have demonstrated that they can improve the effectiveness, efficiency, and safety of Drug Therapy by providing CDTM. It is time to incorporate this valuable professional skill of the contemporary pharmacist as a core component of the delivery of health care services.
Sue Wingate - One of the best experts on this subject based on the ideXlab platform.
-
Cardiovascular Drug Therapy in women.
The Journal of cardiovascular nursing, 2005Co-Authors: Anne P. Spencer, Sue WingateAbstract:Cardiovascular disease has been the leading cause of morbidity and mortality in American women; yet, until recently, there was no mandate to specifically include women in clinical trials of the major cardiovascular Drugs. Despite new regulations, there is still a lack of readily available data for the clinician to use when planning Drug Therapy for women, as many of the Drugs in use today were developed and tested prior to the new regulations being in effect. The purpose of this article is to provide advanced practice nurses with the most current information on the use of cardiovascular Drugs in women. Information on the unique biological features of women is first presented to provide background material for subsequent sections. This is followed by an explanation of pharmacokinetic processes in women to include information on absorption, distribution, and clearance of Drugs. A brief review of the effects of the phases of the menstrual cycle on Drug Therapy is given and then issues related to the profound physiologic changes in pregnancy and subsequent effects on Drug Therapy are reviewed. An analysis of the strength of the available evidence on Drug therapies in women from the major trials on acute coronary syndromes, heart failure, dyslipidemia, atrial fibrillation, and hypertension is provided. Finally, implications for practice, including recommendations for Drug prescription, are summarized.
